Organon & Co (OGN)

Ordinary Shares

Sell: $9.19|Buy: $9.29|Change: 0.10 (-1.07%)

Not yet a customer?

Low cost dealing from £1.50

Choose from our range of SIPP, ISA and Dealing accounts

Open

$9.29

Previous close

$9.38

Trade high

$9.405

Volume

3,357,135

Year high

$19.045

Year low

$8.01

Dividend yield

6.47%

Market capitalisation

$2.41 bn

P/E ratio

3.45

ISIN

US68622V1061

This share can be held in a Dealing account Stocks and shares ISA Lifetime ISA JISA SIPP

Share price

Dividends

	Previous	Latest
Record date	12/05/2025	15/08/2025
Ex-dividend date	12/05/2025	15/08/2025
Payment date	12/06/2025	11/09/2025
Amount	$0.02	$0.02

Performance 17/10/2025

1D | 1M | 3M | 1Y | 3Y ann | 5Y ann | 10Y ann

	Total return (%)
Organon & Co	- 1.07
More...

Company profile

Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.

Sector

Healthcare

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.